Vetr Inc. disclosed Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), hiking its price target to $102.58 earlier today
- Updated: April 20, 2017
Just yesterday Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded 2.29% higher at $117.26. Vertex Pharmaceuticals Incorporated’s 50-day moving average is $101.25 and its 200-day moving average is $87.44. The last stock price is up 34.10% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 1,495,498 shares of VRTX traded hands, down from an average trading volume of 1,867,700
In a report released on Thursday April 20, 2017 Vetr Inc. increased the stock price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $102.58 reporting a possible downside of -0.13%.
Previously on 4/12/2017, Zacks Investment Research released a statement about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) increased the target price from $0.00 to $128.00. At the time, this indicated a possible upside of 0.12%.
Recent Performance Chart
Vertex Pharmaceuticals Incorporated has 52 week low of $71.46 and a 52 week high of $117.99 and has a market capitalization of $0.
In addition to Vetr Inc. reporting its stock price target, a total of 20 brokerages have issued a ratings update on the company. The average stock price target is $110.30 with 8 brokerages rating the stock a strong buy, 10 brokerages rating the stock a buy, 7 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.